Raymond James reiterates Tvardi Therapeutics stock rating on HCC data
Raymond James reiterated an Outperform rating and $10.00 price target for Tvardi Therapeutics (TVRD) after Q3 2026 earnings, citing encouraging data for TTI-101 in HCC and TTI-109's tolerability. The stock is down 73% YTD but appears undervalued, with upward earnings revisions. The HCC readout is delayed to Q1 2027. Other analysts also initiated coverage with buy ratings and price targets ranging from $8.00 to $14.00.


